Prestige BioPharma Statistics

Total Valuation

KRX:950210 has a market cap or net worth of KRW 160.10 billion. The enterprise value is 195.23 billion.

Market Cap	160.10B
Enterprise Value	195.23B

Important Dates

The last earnings date was Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:950210 has 12.02 million shares outstanding. The number of shares has decreased by -0.12% in one year.

Current Share Class	n/a
Shares Outstanding	12.02M
Shares Change (YoY)	-0.12%
Shares Change (QoQ)	-3.44%
Owned by Insiders (%)	30.40%
Owned by Institutions (%)	0.10%
Float	3.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	136.46
PB Ratio	2.02
P/TBV Ratio	0.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.54
EV / Sales	33.26
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.15

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.35.

Current Ratio	1.47
Quick Ratio	1.35
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	-1.92
Interest Coverage	-8.52

Financial Efficiency

Return on equity (ROE) is -11.71% and return on invested capital (ROIC) is -6.11%.

Return on Equity (ROE)	-11.71%
Return on Assets (ROA)	-5.41%
Return on Invested Capital (ROIC)	-6.11%
Return on Capital Employed (ROCE)	-11.01%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	0.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +51.61% in the last 52 weeks. The beta is 1.13, so KRX:950210's price volatility has been higher than the market average.

Beta (5Y)	1.13
52-Week Price Change	+51.61%
50-Day Moving Average	14,224.60
200-Day Moving Average	13,759.35
Relative Strength Index (RSI)	49.22
Average Volume (20 Days)	101,611

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:950210 had revenue of KRW 5.87 billion and -29.85 billion in losses. Loss per share was -496.51.

Revenue	5.87B
Gross Profit	4.65B
Operating Income	-63.11B
Pretax Income	-58.53B
Net Income	-29.85B
EBITDA	-44.53B
EBIT	-63.11B
Loss Per Share	-496.51

Full Income Statement

Balance Sheet

The company has 242.88 billion in cash and 175.12 billion in debt, giving a net cash position of 67.76 billion or 5,637.44 per share.

Cash & Cash Equivalents	242.88B
Total Debt	175.12B
Net Cash	67.76B
Net Cash Per Share	5,637.44
Equity (Book Value)	493.39B
Book Value Per Share	6,610.07
Working Capital	85.94B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -68.80 billion and capital expenditures -22.20 billion, giving a free cash flow of -91.00 billion.

Operating Cash Flow	-68.80B
Capital Expenditures	-22.20B
Free Cash Flow	-91.00B
FCF Per Share	-7,571.17

Full Cash Flow Statement

Margins

Gross Margin	79.25%
Operating Margin	-1,075.25%
Pretax Margin	-997.26%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KRX:950210 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.12%
Shareholder Yield	0.12%
Earnings Yield	-18.65%
FCF Yield	-56.84%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:950210 has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.43
Piotroski F-Score	n/a